seekingalpha.com
Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript
Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript
Neuronetics, Inc.STIMNASDAQ
Loading
Latest News
Loading news...
globenewswire.com
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; proven medical device leader with more than 30 years of experience scaling commercial healthcare businesses MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2025.
globenewswire.com
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
Seasoned leader brings more than 30 years of medical device experience, with a proven track record of growing revenue, earnings, and cash flow across multiple publicly traded healthcare companies Seasoned leader brings more than 30 years of medical device experience, with a proven track record of growing revenue, earnings, and cash flow across multiple publicly traded healthcare companies
defenseworld.net
Analyzing ADB International Group (OTCMKTS:EQUR) & Neuronetics (NASDAQ:STIM)
Neuronetics (NASDAQ: STIM - Get Free Report) and ADB International Group (OTCMKTS:EQUR - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Valuation and Earnings This table compares Neuronetics and
defenseworld.net
Neuronetics, Inc. (NASDAQ:STIM) Short Interest Update
Neuronetics, Inc. (NASDAQ: STIM - Get Free Report) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 8,588,113 shares, a growth of 20.0% from the January 15th total of 7,159,363 shares. Currently, 13.9% of the shares of the stock are sold short. Based on
feeds.benzinga.com
Neuronetics (STIM) Stock Rises 41% After Hours: What's Going On?
Neuronetics shares jumped 41% in after-hours trading following strong preliminary fourth-quarter 2025 revenue results.
globenewswire.com
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basis Full year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basis Achieved positive operating cash flow of $0.9 million in the fourth quarter 2025 Ended 2025 with total cash of $34.1 million, inclusive of cash, cash equivalents and restricted cash MALVERN, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced selected preliminary unaudited financial results for the fourth quarter and full-year 2025.
globenewswire.com
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 12:30 p.m. (ET) the same day. The presentation will be available via the conference portal to registered attendees.
globenewswire.com
TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States
seekingalpha.com
Neuronetics, Inc. (STIM) Q3 2025 Earnings Call Transcript
Neuronetics, Inc. ( STIM ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Keith Sullivan - President, CEO & Director Steven Pfanstiel - Executive VP, Treasurer & CFO Conference Call Participants Mark Klausner - Westwicke Partners, LLC William Plovanic - Canaccord Genuity Corp., Research Division Kyle Edward Winborne - Piper Sandler & Co., Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Neuronetics Third Quarter 2025 Earnings Conference Call.
zacks.com
Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.29 per share a year ago.
globenewswire.com
Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan
Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted pro forma basis versus Q3 2024 Continued cash management improvement, with cash used in operations of $0.8 million in Q3 2025 Strengthened balance sheet in Q3 2025, ending the quarter with $34.5 million of total cash, consisting of cash, cash equivalents, and restricted cash MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2025 and the intention of Keith J.
globenewswire.com
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan.
globenewswire.com
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite DNA Clinics New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite DNA Clinics
globenewswire.com
Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS), announced that it plans to release third quarter 2025 financial and operating results prior to market open on Tuesday, November 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/yxrs8osc . To listen to the conference call on your telephone, participants may register for the call here . While it is not required, it is recommended you join 10 minutes prior to the event start.
globenewswire.com
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services
globenewswire.com
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan.
seekingalpha.com
Neuronetics, Inc. (STIM) Q2 2025 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Keith J. Sullivan - President, CEO & Director Steven E.
zacks.com
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.33 per share a year ago.
globenewswire.com
Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Keith Sullivan, President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 1:30pm Eastern Time the same day. The presentation will be available via the conference portal to registered attendees and presenting companies for 14 days following the event. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. Investor Contact: Mike Vallie or Mark KlausnerICR Healthcare443-213-0499 ir@neuronetics.com Media Contact: EvolveMKD646-517-4220 NeuroStar@evolvemkd.com